2,6-Di-t-butyl-4-[(trimethylsilyl)methylthio]phenol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,6-Di-t-butyl-4-[(trimethylsilyl)methylthio]phenol
• 英文别名: 2,6-di-t-butyl-4[(trimethylsilyl)methyl]thio-phenol；2,6-Di-t-butyl-4[(trimethylsilyl)methylthio]phenol；2,6-ditert-butyl-4-(trimethylsilylmethylsulfanyl)phenol
• 化学式: C₁₈H₃₂OSSi
• 分子量: 324.603
• InChiKey: NQHFAZBCHXYAQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.96
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  45.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,6-Di-t-butyl-4-[(trimethylsilyl)methylthio]phenol 、 单乙基琥珀酰氯 在 sodium hydroxide 作用下， 以 甲醇 、 异丁酰胺 、 水 为溶剂， 生成 2,6-Di-t-butyl-4-[(trimethylsilyl)methylthio]phenol succinic acid ester
  参考文献：
  名称：

  Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents

  摘要：

  本发明涉及以下式的化合物：其中R.sub.1和R.sub.6分别独立为C.sub.1-C.sub.6烷基；R.sub.2、R.sub.3和R.sub.4分别独立为氢或C.sub.1-C.sub.6烷基；R为氢或--C(O)--(CH.sub.2).sub.m--Q，其中Q为氢或--COOH，m为整数1、2、3或4；Z为硫、氧或亚甲基基团；A为C.sub.1-C.sub.4烷基基团；R.sub.5和R.sub.7分别独立为C.sub.1-C.sub.6烷基或--(CH.sub.2).sub.n--(Ar)，其中n为整数0、1、2或3；Ar为苯基或萘基，未取代或取代一个至三个羟基、甲氧基、乙氧基、卤素、三氟甲基、C.sub.1-C.sub.6烷基或--NR.sub.8R.sub.9，其中R.sub.8和R.sub.9分别独立为氢或C.sub.1-C.sub.6烷基；但当R.sub.2和至少一个R.sub.5或R.sub.7为C.sub.1-C.sub.6烷基，且Ar未取代三氟甲基或--NR.sub.8R.sub.9时，则R为--C(O)--(CH.sub.2).sub.m--Q；或其药学上可接受的盐；用于治疗动脉粥样硬化和慢性炎症性疾病；用于抑制细胞因子诱导的VCAM-1和/或ICAM-1表达；用于抑制LDL脂质过氧化；用于降低血浆胆固醇；以及作为抗氧化剂化学添加剂，用于防止有机材料的氧化恶化。

  公开号：

  US05608095A1
• 作为产物：
  描述：

  2,6-二叔丁基-4-巯基苯酚 、 氯甲基三甲基硅烷 在 potassium carbonate 作用下， 以 异丁酰胺 为溶剂， 以1.1 g (34%)的产率得到2,6-Di-t-butyl-4-[(trimethylsilyl)methylthio]phenol
  参考文献：
  名称：

  2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents

  摘要：

  这项发明涉及某些2,6-二烷基-4-硅烷基酚，可用作低密度脂蛋白氧化和抗动脉粥样硬化药物。

  公开号：

  US05155250A1

文献信息

• Method of lowering serum cholesterol levels with
  申请人：Hoechst Marion Roussel, Inc.

  公开号：US05677291A1

  公开（公告）日：1997-10-14

  A method of lowering plasma cholesterol level in a patient with hypercholesterolemia, by administration of a compound of formula (1) ##STR1## wherein: R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently a C.sub.1 -C.sub.6 alkyl group; Z is a thio, oxy or methylene group; A is a C.sub.1 -C.sub.4 alkylene group; and R.sub.5 is a C.sub.1 -C.sub.6 alkyl or --(CH.sub.2).sub.n --(Ar) wherein n is an integer 0, 1, 2 or 3; and Ar is phenyl or napthyl unsubstituted or substituted with one to three substituents selected from the group consisting of hydroxy, methoxy, ethoxy, chloro, fluoro or C.sub.1 -C.sub.6 alkyl.

  一种通过给患有高胆固醇血症的患者施用化合物（1）的方法降低血浆胆固醇水平，其中：R.sub.1、R.sub.2、R.sub.3和R.sub.4各自独立地为C.sub.1-C.sub.6烷基基团；Z为硫、氧或亚甲基基团；A为C.sub.1-C.sub.4烷基基团；R.sub.5为C.sub.1-C.sub.6烷基或--(CH.sub.2).sub.n--(Ar)，其中n为整数0、1、2或3；Ar为苯基或萘基，未取代或经过一个到三个羟基、甲氧基、乙氧基、氯、氟或C.sub.1-C.sub.6烷基的取代。
• 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents
  申请人：Merrell Dow Pharmaceuticals Inc.

  公开号：US05155250A1

  公开（公告）日：1992-10-13

  This invention relates to certain 2,6-di-alkyl-4-silyl-phenols which are useful as inhibitors of LDL lipid peroxidation and as antiatherosclerotic agents.

  这项发明涉及某些2,6-二烷基-4-硅烷基酚，可用作低密度脂蛋白氧化和抗动脉粥样硬化药物。
• Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
  申请人：Hoechst Marion Roussel, Inc.

  公开号：US05608095A1

  公开（公告）日：1997-03-04

  This invention relates to compounds of the formula ##STR1## wherein R.sub.1 and R.sub.6 are each independently C.sub.1 -C.sub.6 alkyl; R.sub.2, R.sub.3 and R.sub.4 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl; R is hydrogen or --C(O)--(CH.sub.2).sub.m --Q wherein Q is hydrogen or --COOH and m is an integer 1, 2, 3 or 4; Z is a thio, oxy or methylene group; A is a C.sub.1 -C.sub.4 alkylene group; R.sub.5 and R.sub.7 are each independently a C.sub.1 -C.sub.6 alkyl or --(CH.sub.2).sub.n --(Ar) wherein n is an integer 0, 1, 2 or 3; and Ar is phenyl or naphthyl unsubstituted or substituted with one to three substituents selected from the group consisting of hydroxy, methoxy, ethoxy, halogen, trifluoromethyl, C.sub.1 -C.sub.6 alkyl, or --NR.sub.8 R.sub.9, wherein R.sub.8 and R.sub.9 are each independently hydrogen or C.sub.1 -C.sub.6 alkyl; with the proviso that when R.sub.2 and at least one of R.sub.5 or R.sub.7 is C.sub.1 -C.sub.6 alkyl, and Ar is not substituted with trifluoromethyl or --NR.sub.8 R.sub.9, then R is --C(O)--(CH.sub.2).sub.m --Q; or a pharmaceutically acceptable salt thereof; useful for the treatment of atherosclerosis and chronic inflammatory disorders; for inhibiting cytokine-induced expression of VCAM-1 and/or ICAM-1; for inhibiting the peroxidation of LDL lipid; for lowering plasma cholesterol; and as antioxidant chemical additives useful for preventing oxidative deterioration in organic materials.

  本发明涉及以下式的化合物：其中R.sub.1和R.sub.6分别独立为C.sub.1-C.sub.6烷基；R.sub.2、R.sub.3和R.sub.4分别独立为氢或C.sub.1-C.sub.6烷基；R为氢或--C(O)--(CH.sub.2).sub.m--Q，其中Q为氢或--COOH，m为整数1、2、3或4；Z为硫、氧或亚甲基基团；A为C.sub.1-C.sub.4烷基基团；R.sub.5和R.sub.7分别独立为C.sub.1-C.sub.6烷基或--(CH.sub.2).sub.n--(Ar)，其中n为整数0、1、2或3；Ar为苯基或萘基，未取代或取代一个至三个羟基、甲氧基、乙氧基、卤素、三氟甲基、C.sub.1-C.sub.6烷基或--NR.sub.8R.sub.9，其中R.sub.8和R.sub.9分别独立为氢或C.sub.1-C.sub.6烷基；但当R.sub.2和至少一个R.sub.5或R.sub.7为C.sub.1-C.sub.6烷基，且Ar未取代三氟甲基或--NR.sub.8R.sub.9时，则R为--C(O)--(CH.sub.2).sub.m--Q；或其药学上可接受的盐；用于治疗动脉粥样硬化和慢性炎症性疾病；用于抑制细胞因子诱导的VCAM-1和/或ICAM-1表达；用于抑制LDL脂质过氧化；用于降低血浆胆固醇；以及作为抗氧化剂化学添加剂，用于防止有机材料的氧化恶化。
• Method of inhibiting vascular cell adhesion molecule-1 and treating
  申请人：Hoechst Marion Rousssel, Inc.

  公开号：US05795876A1

  公开（公告）日：1998-08-18

  Methods useful for inhibiting VCAM-1 and for treating chronic inflammatory conditions in a patient in need thereof are disclosed comprising administering to the patient effective amounts of a compound of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently a C.sub.1 -C.sub.6 alkyl group; Z is a thio, oxy or methylene group; A is a C.sub.1 -C.sub.4 alkylene group; R.sub.5 is a C.sub.1 -C.sub.6 alkyl or --(CH.sub.2).sub.n --(Ar) wherein n is an integer 0, 1, 2 or 3; and Ar is phenyl or naphthyl unsubstituted or substituted with one to three substituents selected from the group consisting of hydroxy, methoxy, ethoxy, chloro, fluoro or C.sub.1 -C.sub.6 alkyl; are disclosed.

  本文揭示了用于抑制VCAM-1并治疗患有慢性炎症症状的患者的方法，包括向患者施用化合物的有效量，其化学式为##STR1##其中R.sub.1、R.sub.2、R.sub.3和R.sub.4分别独立为C.sub.1-C.sub.6烷基基团；Z为硫、氧或亚甲基基团；A为C.sub.1-C.sub.4烷基基团；R.sub.5为C.sub.1-C.sub.6烷基或--(CH.sub.2).sub.n--(Ar)其中n为整数0、1、2或3；Ar为苯或萘，未取代或取代一个至三个亚甲基、甲氧基、乙氧基、氯、氟或C.sub.1-C.sub.6烷基的取代基。